 Connection
Virginia Borges to ErbB Receptors
This is a "connection" page, showing publications Virginia Borges has written about ErbB Receptors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.063 |
|
|
|
-
Moulder SL, Borges VF, Baetz T, Mcspadden T, Fernetich G, Murthy RK, Chavira R, Guthrie K, Barrett E, Chia SK. Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC). Clin Cancer Res. 2017 Jul 15; 23(14):3529-3536.
Score: 0.025
-
Sartorius CA, Hanna CT, Gril B, Cruz H, Serkova NJ, Huber KM, Kabos P, Schedin TB, Borges VF, Steeg PS, Cittelly DM. Estrogen promotes the brain metastatic colonization of triple negative breast cancer cells via an astrocyte-mediated paracrine mechanism. Oncogene. 2016 06 02; 35(22):2881-92.
Score: 0.023
-
Hirsch FR, Mok TS, Borges V, Bunn PA. Molecularly targeted therapy: when to stop and when to continue? Lancet Oncol. 2010 Aug; 11(8):709-11.
Score: 0.016
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|